Overview
- 21 inspections across 21 sites are on record.
- 53 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-03-23.
At a glance
Inspections
21
Sites
21
Observations
53
Career since
Jan 2024
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Jubilant DraxImage Radiopharmacies | 23 Mar 2026 | Human Drugs | View 483 → |
| Cardinal Health 414, LLC | 18 Mar 2026 | Human Drugs | View 483 → |
| Gilead Sciences, Inc. | 18 Feb 2026 | Human Drugs | View 483 → |
| K.C. Pharmaceuticals, Inc | 13 Feb 2026 | Human Drugs | View 483 → |
| Hunan Xiangyikang Pharmaceutical Co., Ltd. | 21 Nov 2025 | Human Drugs | On file |
Sites inspected
Jubilant DraxImage RadiopharmaciesMobile, United States1 insp.
Cardinal Health 414, LLCJackson, United States1 insp.
Gilead Sciences, Inc.La Verne, United States1 insp.
K.C. Pharmaceuticals, IncPomona, United States1 insp.
Hunan Xiangyikang Pharmaceutical Co., Ltd.Yiyang, China1 insp.
Co-investigators
Investigators who share inspections with this person.
Crystal Monroy5 shared
Tareq W Haddad3 shared
Rowena S Nguyen3 shared
Youkeun Kim3 shared
Ngozi G Offor2 shared
Katherine E Jacobitz2 shared
Thuy Tram L Nguyen2 shared
Andrew Le2 shared
Elvis Patel1 shared
Nathan E Hellman1 shared
Full investigator report
Get the verbatim findings behind Pearl C Ozuruigbo's 53 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site